LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor

Abstract

The bromodomain‐containing proteins BRD9 and BRD7 are part of the human SWI/SNF chromatin‐remodeling complexes BAF and PBAF. To date, no selective inhibitor for BRD7/9 has been reported despite its potential value as a biological tool or as a lead for future therapeutics. The quinolone‐fused lactam LP99 is now reported as the first potent and selective inhibitor of the BRD7 and BRD9 bromodomains. Development of LP99 from a fragment hit was expedited through balancing structure‐based inhibitor design and biophysical characterization against tractable chemical synthesis: Complexity‐building nitro‐Mannich/lactamization cascade processes allowed for early structure–activity relationship studies whereas an enantioselective organocatalytic nitro‐Mannich reaction enabled the synthesis of the lead scaffold in enantioenriched form and on scale. This epigenetic probe was shown to inhibit the association of BRD7 and BRD9 to acetylated histones in vitro and in cells. Moreover, LP99 was used to demonstrate that BRD7/9 plays a role in regulating pro‐inflammatory cytokine secretion.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 27

1. 1.

   Wu WJ, Hu KS, Chen DL, Zeng ZL, Luo HY, Wang F, Wang DS, Wang ZQ, He F, Xu RH. Eur. J. Clin. Invest. 2013;43:131-140.

   Not in our library10.1111/eci.12024

2. 2.

   Drost J, et al. Nat. Cell Biol. 2010;12:380-389.

   Not in our library10.1038/ncb2038

3. 3.

   Chiu YH, Lee JY, Cantley LC. Mol. Cell. 2014;54:193-202.

   Not in our library10.1016/j.molcel.2014.02.016

4. 4.

   Harte MT, O′Brien GJ, Ryan NM, Gorski JJ, Savage KI, Crawford NT, Mullan PB, Harkin DP. Cancer Res. 2010;70:2538-2547.

   Not in our library10.1158/0008-5472.can-09-2089

5. 5.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

6. 6.

   Scotto L, et al. Mol. Cancer. 2008;7:58.

   Not in our library10.1186/1476-4598-7-58

7. 7.

   667-678.

   Not in our library

8. 8.

   Agalioti T, Lomvardas S, Parekh B, Yie J, Maniatis T, Thanos D. Cell. 2000;103.

   Not in our library10.1016/s0092-8674(00)00169-0

9. 9.

   Cullen SJ, Ponnappan S, Ponnappan U. Mol. Immunol. 2009;47.

   Not in our library10.1016/j.molimm.2009.09.008

10. 10.

    Ramirez-Carrozzi VR, Nazarian AA, Li CC, Gore SL, Sridharan R, Imbalzano AN, Smale ST. Genes Dev. 2006;20.

    Not in our library10.1101/gad.1383206

11. 11.

    540-546.

    Not in our library

12. 12.

    Guetzoyan L, et al. MedChemComm. 2014;5.

    Not in our library

13. 13.

    Fedorov O, et al. J. Med. Chem. 2014;57.

    Not in our library10.1021/jm401568s

14. 14.

    Lovering F, Bikker J, Humblet C. J. Med. Chem. 2009;52:6752-6756.

    Not in our library10.1021/jm901241e

15. 15.

    Nicolaou KC, Chen JS. Chem. Soc. Rev. 2009;38:2993-3009.

    Not in our library10.1039/b903290h

16. 16.

    Chaikuad A, Petros AM, Fedorov O, Xu J, Knapp S. MedChemComm. 2014;5:1843-1848.

    Not in our library

17. 17.

    Yin J, Buchwald SL. J. Am. Chem. Soc. 2002;124:6043-6048.

    Not in our library10.1021/ja012610k

18. 18.

    Araki K, Tada K-i, Abe M, Mutai T. J. Chem. Soc. Perkin Trans. 2. 1998;1391-1396.

    Not in our library

19. 19.
    Stereoselective, nitro-Mannich/lactamisation cascades for the direct synthesis of heavily decorated 5-nitropiperidin-2-ones and related heterocycles · 2012

    Not checked
20. 20.

    Beadle CD, Boot J, Camp NP, Dezutter N, Findlay J, Hayhurst L, Masters JJ, Penariol R, Walter MW. Bioorg. Med. Chem. Lett. 2005;15:4432-4437.

    Not in our library10.1016/j.bmcl.2005.07.038

21. 21.

    Johnson KM, Rattley MS, Sladojevich F, Barber DM, Nuñez MG, Goldys AM, Dixon DJ. Org. Lett. 2012;14:2492-2495.

    Not in our library

22. 22.

    86-94.

    Not in our library

23. 23.

    Tarcsay Á, Keserű GM. Drug Discovery Today. 2015;20.

    Not in our library10.1016/j.drudis.2014.09.014

24. 24.

    Ferenczy GG, Keserű GM. Drug Discovery Today. 2010;15.

    Not in our library10.1016/j.drudis.2010.08.013

25. 25.

    Philpott M, Rogers CM, Yapp C, Wells C, Lambert JP, Strain-Damerell C, Burgess-Brown NA, Gingras AC, Knapp S, Müller S. Epigenet. Chromatin. 2014;7:14.

    Not in our library10.1186/1756-8935-7-14

26. 26.

    Deplus R, et al. EMBO J. 2013;32:645-655.

    Not in our library10.1038/emboj.2012.357

27. 27.

    Scheinecker C, Smolen J, Yasothan U, Stoll J, Kirkpatrick P. Nat. Rev. Drug Discovery. 2009;8:273-274.

    Not in our library10.1038/nrd2863

Cited by papers we hold 4

• Epigenetics-targeted drugs: current paradigms and future challenges · 2024
  No notice
• Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy · 2021
  No notice
• The BRPF1 bromodomain is a molecular reader of di-acetyllysine · 2020
  Not checked
• A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain · 2016
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.